Advertisement

Role of the US Food and Drug Administration in Cancer Drug Development

  • Ann T. Farrell
  • Ramzi N. Dagher
  • Richard Pazdur
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

The US Food and Drug Administration (FDA) oversees the development of agents to diagnose, cure, mitigate, treat, or prevent cancer. The FDA’s mission statement is “The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health” [1]. The FDA accomplishes its mission through meetings with individual investigators and sponsors, review of investigational new drug (IND) and new drug applications (NDA), facilities inspections, approval of marketing and licensing applications, and the administration of grant programs.

Keywords

Clinical Hold Oncology Drug Advisory Committee 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    FDA Mission statement at http://www.fda.gov/opacom/morechoices/mission.html (accessed 6/10/08)
  2. 2.
    Chapter 21 Code of Federal Regulations (CFR) 312Google Scholar
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
    Guidance for Industry, IND Exemptions for Studies of Lawfully Marketed Drugs or Biological Products for the Treatment of Cancer, issued January 2004. http://www.fda.gov/cder/Guidance/6036fnl.pdf (accessed 11/18/08)
  8. 8.
    CFR 312.23Google Scholar
  9. 9.
    Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies, issued January 2006. http://www.fda.gov/CDER/guidance/7086fnl.htm (accessed 11/28/08)
  10. 10.
    Innovation or Stagnation, Challenge and Opportunity on the Critical Path to New Medical Products, March 2004 at http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html (accessed 6/17/08)
  11. 11.
    CFR 312.23 (a)(7)Google Scholar
  12. 12.
    Farrell AT, Leighton J, Williams G, and Pazdur R. How Oncology Drug Development Differs from Other Fields. In Handbook of Anticancer Drug Development. Budman DR, Calvert AH, Rowinsky EK (eds). Lippincott Williams & Wilkens, Baltimore, MD, 2003. pp. 3–10Google Scholar
  13. 13.
    International Conference on Harmonization Draft Consensus Guideline Document S9 Nonclinical Evaluation for Anticancer Pharmaceuticals, November 2008. http://www.ich.org/LOB/media/MEDIA4917.pdf (accessed 12/2/08)
  14. 14.
    International Conference on Harmonization Document M3 “Guidance for Industry: Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals.” July 1997. http://www.fda.gov/CDER/guidance/1855fnl.pdf (accessed 11/28/08)
  15. 15.
    United States Department of Health and Human Services, Food and Drug Administration. “Single Dose Acute Toxicity Testing for Pharmaceuticals; Revised Guidance.” Federal Register 1996 August 26; 61(166): 43934–43935Google Scholar
  16. 16.
    DeGeorge JJ, Ahn CH, Andrews P, Brower M, Gorgio D, Goheer MA, Lee-Ham DY, McGuinn WD, Schmidt W, Sun CJ, and Tripathi S. Regulatory Considerations for Preclinical Development of Anticancer Drugs. Cancer Chemotherapy and Pharmacology 1998; 41: 173–185PubMedCrossRefGoogle Scholar
  17. 17.
    The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products: Note for Guidance on Repeated Dose Toxicity. July 2000. http://www.emea.europa.eu/pdfs/human/swp/104299en.pdf (accessed 11/28/08)
  18. 18.
    The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products: Note for Guidance on Non-clinical Local Tolerance Testing of Medicinal Products. March 2001. http://www.emea.europa.eu/pdfs/human/swp/214500en.pdf (accessed 11/28/08)
  19. 19.
    International Conference on Harmonization Document S2A Document “Guideline for Industry: Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals.” April 1996. http://www.fda.gov/cder/guidance/ichs2a.pdf (accessed 11/28/08)
  20. 20.
    International Conference on Harmonization Document S1A Document “Guideline for Industry: The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals.” March 1996. http://www.fda.gov/Cder/guidance/ichs1a.pdf (accessed 11/28/08)
  21. 21.
    International Conference on Harmonization Document S6 “Guidance for Industry Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.” July 1997. http://www.fda.gov/cder/guidance/1859fnl.pdf (accessed 11/28/08)
  22. 22.
    International Conference on Harmonization Document S1B Document “Guidance for Industry: Testing for Carcinogenicity of Pharmaceuticals.” July 1997. http://www.fda.gov/Cder/Guidance/1854fnl.pdf (accessed 11/28/08)
  23. 23.
    International Conference on Harmonization Document S1C Document “Guideline for Industry: Dose Selection for Carcinogenicity Studies of Pharmaceuticals.” March 1995. http://www.ich.org/cache/compo/502-272-1.html (accessed 11/28/08)
  24. 24.
    International Conference on Harmonization Document S1C (R) Document “Guidance for Industry: Addendum to Dose Selection for Carcinogenicity Studies of Pharmaceuticals: Addition of a Limit Dose and Related Notes.” March 1995. http://www.ich.org/cache/compo/502-272-1.html (accessed 11/28/08)
  25. 25.
    The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products: Note for Guidance on Carcinogenic Potential. July 2002. http://www.emea.europa.eu/pdfs/human/swp/287700en.pdf (accessed 11/28/08)
  26. 26.
    International Conference on Harmonization Document S7A “Guidance for Industry: Safety Pharmacology Studies for Human Pharmaceuticals.” July 2001. http://www.fda.gov/Cder/Guidance/4461fnl.pdf (accessed 11/28/08)
  27. 27.
    International Conference on Harmonization Document S7B “The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals.” October 2005. http://www.fda.gov/cder/Guidance/6885fnl.htm (accessed 11/28/08)
  28. 28.
    International Conference on Harmonization Document E14 “The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs.” May 2005. http://www.fda.gov/cder/guidance/6922fnl.htm (accessed 11/28/08)
  29. 29.
  30. 30.
    International Conference on Harmonization “Guidance for Industry E6 Good Clinical Practice Consolidated Guidance.” April 1996. http://www.fda.gov/cder/guidance/959fnl.pdf (accessed 5/6/08)
  31. 31.
    CFR 312.32Google Scholar
  32. 32.
    CFR 312.33Google Scholar
  33. 33.
  34. 34.
  35. 35.
  36. 36.
    FDA Informed Consent information at http://www.fda.gov/oc/ohrt/IRBs/informedconsent.html#general (accessed 6/17/08)
  37. 37.
  38. 38.
    CFR 50. 50-56Google Scholar
  39. 39.
    CFR 312.7 (d)(1)Google Scholar
  40. 40.
    Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees, May 8, 2002. http://www.fda.gov/cber/gdlns/clindatmon.htm (accessed 5/6/08)
  41. 41.
    Guidance for Industry: Financial Disclosure by Clinical Investigators; issued March 2001. http://www.fda.gov/oc/guidance/financialdis.html (accessed 11/28/08)
  42. 42.
    Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products, May 1998. http://www.fda.gov/CDER/GUIDANCE/1397fnl.pdf (accessed 11/28/08)
  43. 43.
    CFR, Parts 314.500 to 314.530Google Scholar
  44. 44.
    Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics; issued May 2007. http://www.fda.gov/CbER/gdlns/clintrialend.htm (accessed 11/28/08)
  45. 45.
    Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, Verbois L, Morse D, Jee JM, Pope S, Harapanhalli R, Dagher R, Farrell A, Justice R, and Pazdur R. Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma. Clinical Cancer Research 2007; 13(8): 2318–2322PubMedCrossRefGoogle Scholar
  46. 46.
    Dagher R, Johnson J, Williams G, Keegan P, and Pazdur R. Accelerated Approval of Oncology Products: A Decade of Experience. Journal of the National Cancer Institute 2004; 96: 1500–1509PubMedCrossRefGoogle Scholar
  47. 47.
    Food and Drug Administration Amendments Act of 2007, Public Law 110–85Google Scholar
  48. 48.
    Farrell AT, Papadouli I, Hori A, Harczy M, Harrison B, Asakura W, Marty M, Dagher R, and Pazdur R. The Advisory Process for Anticancer Drug Regulation: A Global Perspective. Annals of Oncology 2006 June; 17(6):889–996PubMedCrossRefGoogle Scholar
  49. 49.
    Rettig RA, Earley LE, and Merrill RA (eds). Institute of Medicine: Food and Drug Administration Advisory Committees. National Academy Press, Washington, DC, 1992Google Scholar
  50. 50.
    Dagher RN and Pazdur R. Chapter 18: Clinical Trial Design and Regulatory Issues. In Antiangiogenic Cancer Therapy. Abbruzzese JL, Davis D, and Herbst R (eds). Taylor and Francis, Boca Raton, 2007Google Scholar
  51. 51.
  52. 52.
    CFR 316.20 (b)(8)(i,ii)Google Scholar
  53. 53.
    Orphan Drugs Product Development at http://www.fda.gov/orphan/index.htm
  54. 54.
    Best Pharmaceuticals for Children Act, amended to the Federal Food, Drug and Cosmetic Act, Public Law 107–109, 1789, 2002Google Scholar
  55. 55.
    Pediatric Research Equity Act, Public Law 108–155, 2003Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ann T. Farrell
    • 1
  • Ramzi N. Dagher
  • Richard Pazdur
  1. 1.Division of Hematology ProductsOffice of Oncology Drug Products (OODP), Center for Drug Evaluation and Research, US Food and Drug AdministrationSilver SpringUSA

Personalised recommendations